Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, Published online: 19 December 2018; doi:10.1038/s41586-018-0792-9Neoantigen-targeting vaccines are a feasible therapy for tumours with a low mutation burden and immunologically 'cold' tumour microenvironment, as neoantigen-specific T cells from the peripheral blood migrate into intracranial glioblastoma, thereby altering the immune milieu of the glioblastoma. (Source: Nature AOP)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2UWoAnc